Clinical trials: Brain Structure
Epilepsy
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic…
- Trial name
- ALEX-MT (NCT00520741)
- Testing
- Lacosamide
- Where
- 158 sites in United States, Australia and 11 more
- Volunteers
- 426 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Mild Cognitive Impairment, Dementia
Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment
Validate speech analysis AI models: To contrast the accuracy of acceXible's platform as a screening tool in the detection of people with cognitive impairment and mild dementia.
- Trial name
- NCT05340218
- Testing
- Speech analysis
- Where
- Spain
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Accexible
Parkinson's Disease
Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.
- Trial name
- NCT00346827
- Testing
- Apomorphine Nasal Powder
- Volunteers
- 36 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Parkinson Disease (PD), Idiopathic Parkinson's Disease
Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease
This is a randomized, placebo-controlled, double-blind, dose-finding phase 1b study with the purpose to assess the safety, immunogenicity and pharmacodynamics of TRB-001 in early idiopathic Parkinson's Disease patients.
- Trial name
- NCT07840027
- Testing
- TRB-001
- Where
- Austria
- Volunteers
- 36 people
- Sponsor
- Tridem Bioscience FlexCo
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Carotid Artery Disease
Proximal Protection With The Mo.Ma Device During Carotid Stenting
The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery…
- Trial name
- ARMOUR (NCT00744523)
- Testing
- Mo.Ma cerebral protection device
- Where
- 2 sites in United States
- Volunteers
- 262 people
- Sponsor
- Medtronic Endovascular
Tourette Syndrome, Tourette Syndrome in Adolescence
A Study to Explore the Effect of Sepranolone in Tourette Syndrome
The study was an open-label, randomized, multicenter, parallel, Phase 2a study in adolescents and adult patients with Tourette syndrome that aimed to explore the efficacy of Sepranolone as a treatment for Tourette syndrome, by…
- Trial name
- NCT05434546
- Testing
- Sepranolone
- Where
- 2 sites in Denmark
- Volunteers
- 26 people
- Sponsor
- Asarina Pharma
Epilepsy
The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin
The purpose of this study is to investigate the effects of multiple-dose administration of BIA 2-093 on the steady-state pharmacokinetics of digoxin in healthy subjects.
- Trial name
- NCT02172742
- Testing
- BIA 2-093, Digoxin
- Where
- Portugal
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Dementia With Lewy Bodies
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB.
- Trial name
- NCT05869669
- Testing
- Neflamapimod
- Where
- 40 sites in United States, Netherlands and 1 more
- Volunteers
- 159 people
- Sponsor
- EIP Pharma Inc
Alzheimer's Disease
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01689246
- Testing
- TRx0237 150 mg/day, TRx0237 250 mg/day
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 891 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer s Disease, MCI Conversion to Dementia
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Trial name
- NCT07701161
- Where
- 5 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Neurogen Biomarking LLC
Acromegaly
Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®
Check the pharmacodynamics of the drug octreotide acetate LAR 30 mg imported and distributed by Chemical Laboratory Pharmaceutical Bergamo Ltda.
- Trial name
- NCT01086982
- Testing
- Octreotide acetate LAR, Sandostatin LAR ® (octreotide acetate LAR) 30 MG
- Where
- Brazil
- Volunteers
- 16 people
- Sponsor
- Azidus Brasil
Alzheimer's Disease
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
The purpose of this study is to assess the safety and efficacy of Dimebon in combination with donepezil (Aricept) in the treatment of Alzheimer's disease.
- Trial name
- NCT00704782
- Testing
- dimebon
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medivation, Inc.
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Pompe Disease (Late-onset)
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
This is a phase 3 double-blind randomized study to study the efficacy and safety of intravenous ATB200 Co-administered with oral AT2221 in adult subjects with Late Onset Pompe Disease compared with Alglucosidase Alfa/placebo.
- Trial name
- PROPEL (NCT03729362)
- Testing
- Cipaglucosidase Alfa, Miglustat, Alglucosidase Alfa
- Where
- 73 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Amicus Therapeutics
Tyrosinemia, AKU
Evaluation of TYR Sphere in France
10 participants aged 3 years and over with tyrosinaemia or alkaptonuria will be prescribed Tyr sphere following an assessment of their individual needs by their dietitian.
- Trial name
- TYR sphere Fra (NCT04761588)
- Testing
- Tyr sphere
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Vitaflo International, Ltd
Idiopathic Parkinson's Disease
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).
- Trial name
- TOZ-PD (NCT02453386)
- Testing
- tozadenant
- Where
- 71 sites in United States, Austria and 5 more
- Volunteers
- 449 people
- Sponsor
- Biotie Therapies Inc.
Mild Traumatic Brain Injury
SSVEP Evaluation of Brain Function
The investigational device used in this clinical investigation, the Nurochek Headset, is a portable electroencephalogram (EEG) headset which delivers a visual stimulus and measures a VEP.
- Trial name
- NCT05614570
- Testing
- SSVEP Device, SCAT5
- Where
- Australia
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Headsafe MFG
Alzheimer Disease
Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease
The goal of this clinical study is to evaluate satisfaction with the use of orodispersible Memantine (OD) versus conventional Memantine tablets (MTb) using the validate SATMED-Q in patients with moderate to severe Alzheimer's…
- Trial name
- NCT07417670
- Testing
- Memantine, Memantine Oral Tablet
- Where
- 4 sites in Mexico
- Volunteers
- 105 people
- Sponsor
- Carnot Laboratories
Parkinson Disease, Deep Brain Stimulation
Validation of HaGuide Software Module Accuracy in Mapping STN Boundaries in Parkinson's Disease Patients Who Underwent DBS Procedure
HaGuide version 1.0 (Neuro-Omega Ltd.) is a software module add-on to the FDA cleared Neuro-Omega System (K123796). It was designed to facilitate the use of Neuro-Omega's system by automatically mapping visually the depth of STN…
- Trial name
- NCT03363724
- Testing
- HaGuide version 1.0 software module
- Volunteers
- 103 people
- Sponsor
- Alpha Omega Engineering Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.